FR2739292B1 - Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations - Google Patents

Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations

Info

Publication number
FR2739292B1
FR2739292B1 FR9511411A FR9511411A FR2739292B1 FR 2739292 B1 FR2739292 B1 FR 2739292B1 FR 9511411 A FR9511411 A FR 9511411A FR 9511411 A FR9511411 A FR 9511411A FR 2739292 B1 FR2739292 B1 FR 2739292B1
Authority
FR
France
Prior art keywords
pharmaceutical composition
nucleic acids
composition useful
transfecting nucleic
transfecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9511411A
Other languages
English (en)
Other versions
FR2739292A1 (fr
Inventor
Francis Blanche
Beatrice Cameron
Joel Crouzet
Vincent Thuillier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Priority to FR9511411A priority Critical patent/FR2739292B1/fr
Priority to ZA968109A priority patent/ZA968109B/xx
Priority to HU9900317A priority patent/HUP9900317A3/hu
Priority to CZ98947A priority patent/CZ94798A3/cs
Priority to JP9513192A priority patent/JPH11512704A/ja
Priority to BR9610719A priority patent/BR9610719A/pt
Priority to KR1019980702282A priority patent/KR19990063814A/ko
Priority to SK400-98A priority patent/SK40098A3/sk
Priority to AU71361/96A priority patent/AU720697B2/en
Priority to CA002231064A priority patent/CA2231064A1/fr
Priority to US09/043,856 priority patent/US6153597A/en
Priority to EP96932668A priority patent/EP0854930A1/fr
Priority to PCT/FR1996/001516 priority patent/WO1997012051A1/fr
Priority to IL12384996A priority patent/IL123849A0/xx
Publication of FR2739292A1 publication Critical patent/FR2739292A1/fr
Application granted granted Critical
Publication of FR2739292B1 publication Critical patent/FR2739292B1/fr
Priority to MXPA/A/1998/001920A priority patent/MXPA98001920A/xx
Priority to NO981322A priority patent/NO981322L/no
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR9511411A 1995-09-28 1995-09-28 Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations Expired - Fee Related FR2739292B1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
FR9511411A FR2739292B1 (fr) 1995-09-28 1995-09-28 Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
ZA968109A ZA968109B (en) 1995-09-28 1996-09-26 Pharmaceutical composition which is useful for the transfection of nucleic acids and uses thereof
EP96932668A EP0854930A1 (fr) 1995-09-28 1996-09-27 Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
JP9513192A JPH11512704A (ja) 1995-09-28 1996-09-27 核酸のトランスフェクションに有用な医薬組成物及びその使用
BR9610719A BR9610719A (pt) 1995-09-28 1996-09-27 Composição farmacêutica útil para a tranfecção de ao menos um ácido nucléico utilização desta composição e de um composto associando propiedades de fixão de dna a uma capacidade de vetorização nu clear deste dna
KR1019980702282A KR19990063814A (ko) 1995-09-28 1996-09-27 핵산 형질감염용으로 유용한 약학 조성물 및 이의 용도
SK400-98A SK40098A3 (en) 1995-09-28 1996-09-27 Pharmaceutical composition useful for nucleic acid transfection, and use thereof
AU71361/96A AU720697B2 (en) 1995-09-28 1996-09-27 Pharmaceutical composition which is useful for the transfection of nucleic acids, and uses thereof
HU9900317A HUP9900317A3 (en) 1995-09-28 1996-09-27 Pharmaceutical composition useful for nucleic acid transfection, and use thereof
US09/043,856 US6153597A (en) 1995-09-28 1996-09-27 Pharmaceutical composition useful for nucleic acid transfection, and use thereof
CZ98947A CZ94798A3 (cs) 1995-09-28 1996-09-27 Farmaceutická kompozice použitelná pro transfekci nukleových kyselin a její použití
PCT/FR1996/001516 WO1997012051A1 (fr) 1995-09-28 1996-09-27 Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
CA002231064A CA2231064A1 (fr) 1995-09-28 1996-09-27 Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
IL12384996A IL123849A0 (en) 1995-09-28 1996-09-28 Pharmaceutical composition useful for nucleic acid transfection and use thereof
MXPA/A/1998/001920A MXPA98001920A (en) 1995-09-28 1998-03-11 Pharmaceutical composition useful for the transfection of nucleic acids and its u
NO981322A NO981322L (no) 1995-09-28 1998-03-24 Farmas÷ytiske preparater for bruk ved nukleinsyretransfeksjon, og deres anvendelse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9511411A FR2739292B1 (fr) 1995-09-28 1995-09-28 Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations

Publications (2)

Publication Number Publication Date
FR2739292A1 FR2739292A1 (fr) 1997-04-04
FR2739292B1 true FR2739292B1 (fr) 1997-10-31

Family

ID=9483020

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9511411A Expired - Fee Related FR2739292B1 (fr) 1995-09-28 1995-09-28 Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations

Country Status (15)

Country Link
US (1) US6153597A (fr)
EP (1) EP0854930A1 (fr)
JP (1) JPH11512704A (fr)
KR (1) KR19990063814A (fr)
AU (1) AU720697B2 (fr)
BR (1) BR9610719A (fr)
CA (1) CA2231064A1 (fr)
CZ (1) CZ94798A3 (fr)
FR (1) FR2739292B1 (fr)
HU (1) HUP9900317A3 (fr)
IL (1) IL123849A0 (fr)
NO (1) NO981322L (fr)
SK (1) SK40098A3 (fr)
WO (1) WO1997012051A1 (fr)
ZA (1) ZA968109B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2750704B1 (fr) 1996-07-04 1998-09-25 Rhone Poulenc Rorer Sa Procede de production d'adn therapeutique
US6383811B2 (en) * 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
IT1299583B1 (it) * 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
DE19925143A1 (de) * 1999-06-02 2000-12-07 Aventis Pharma Gmbh Neue liposomale Vektorkomplexe und deren Verwendung für die Gentherapie
DE19929104A1 (de) * 1999-06-24 2000-12-28 Aventis Pharma Gmbh Neue Vektorkomplexe und deren Verwendung für die Gentherapie
FR2814370B1 (fr) * 2000-09-22 2004-08-20 Centre Nat Rech Scient Utilisation d'un complexe acide nucleique/pei pour le ciblage de cellules souches du cerveau
IL156132A0 (en) * 2000-11-27 2003-12-23 Yissum Res Dev Co Transfection of human embryonic stem cells
JP2005511761A (ja) * 2001-07-10 2005-04-28 ノース・キャロライナ・ステイト・ユニヴァーシティ ナノ粒子送達ビヒクル
FR2829136B1 (fr) 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
JP5407862B2 (ja) * 2006-10-04 2014-02-05 サントル・ナシオナル・ドゥ・ラ・ルシェルシュ・シアンティフィーク（セーエヌエールエス） ｓｉＲＮＡおよび脂質性４，５−二置換２−デオキシストレプタミン環アミノグリコシド誘導体を含む組成物ならびにその用途
EP3034539A1 (fr) * 2014-12-19 2016-06-22 Ethris GmbH Compositions pour l'introduction d'acides nucléiques dans des cellules

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646161B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) * 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
SG54115A1 (en) * 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
FR2722506B1 (fr) * 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations

Also Published As

Publication number Publication date
EP0854930A1 (fr) 1998-07-29
JPH11512704A (ja) 1999-11-02
FR2739292A1 (fr) 1997-04-04
HUP9900317A3 (en) 2001-10-29
WO1997012051A1 (fr) 1997-04-03
MX9801920A (es) 1998-08-30
BR9610719A (pt) 1999-07-13
CZ94798A3 (cs) 1998-07-15
KR19990063814A (ko) 1999-07-26
IL123849A0 (en) 1998-10-30
AU720697B2 (en) 2000-06-08
AU7136196A (en) 1997-04-17
SK40098A3 (en) 1998-09-09
NO981322D0 (no) 1998-03-24
ZA968109B (en) 1997-04-21
CA2231064A1 (fr) 1997-04-03
US6153597A (en) 2000-11-28
NO981322L (no) 1998-03-24
HUP9900317A2 (hu) 1999-05-28

Similar Documents

Publication Publication Date Title
FR2732223B1 (fr) Composition pharmaceutique pour administration transdermique
FR2740686B1 (fr) Formulation pharmaceutique lyophilisee stable
FR2734483B1 (fr) Forme d'administration pharmaceutique comprenant de l'oxybutynine
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
FR2737118B1 (fr) Composition dermatologique ou pharmaceutique, procede de preparation et utilisation
FR2739292B1 (fr) Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
DE59608156D1 (de) Arzneimittelvorbereitungen enthaltend ein enantiomer von ipratropiumbromid mit verlängerter wirkungsdauer
FR2758459B1 (fr) Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
LV12044A (lv) Stabili reagenti ar radioaktivu izotopu iezimetu farmaceitisku preparatu iegusanai
HUP9801207A3 (en) Therapeutic compositions for transfecting nucleic acids and use thereof
DE69633333D1 (de) Diphosphonatderivate von therapeutischen substanzen
NO973250D0 (no) Preparater for avlevering av antigener
FR2633182B1 (fr) Composition pharmaceutique anticancereuse et methode d'utilisation de l'invention
FR2737408B1 (fr) Utilisation d'un antagoniste de bradykinine dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
ITMI962476A0 (it) Agente polimerico per la filtrazione degli ultravioletti e processo per la sua preparazione
FR2752422B1 (fr) Composition pharmaceutique contenant des acides 4-oxo-butanoiques
FR2700956B1 (fr) Composition cosmetique et pharmaceutique et procede pour sa preparation.
NO964743D0 (no) Matriks-system for transdermal avgivelse av ibuprofen og fremgangsmåte for fremstilling derav
DZ1965A1 (fr) Composition pharmaceutique nouvelle.
FR2730163B1 (fr) Nouvelle composition pharmaceutique contenant la trimebutine et son procede de preparation
DE69603578D1 (de) Synthese von tetrafluorethylen
BR9610851A (pt) Composto processo de preparação de composto medicamento composição farmacêuticas e utilização do composto
FR2718024B1 (fr) Médicament et composition pharmaceutique pour le traitement de l'inflammation.
FR2738841B1 (fr) Procede de polymerisation de sequences d'acides nucleiques et ses applications
AU3578795A (en) Concrete products for promotion of afforestation

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse